Sophia Antipolis, France.
Nicox S.A. (NYSE Euronext Paris: COX) today announced the completion of the acquisition of Doliage, a privately-held French ophthalmic company. The acquisition is part of Nicox’s strategy to develop an ophthalmic commercial infrastructure in the five major European markets and provides Nicox with an established and profitable ophthalmic business in France.
For more information, please refer to:
- Press release dated September 16, 2014: Nicox continues European ophthalmic expansion with acquisition of Doliage in France
- Press release dated September 25, 2014 (in French): Emission par Nicox de 2 235 134 actions en rémunération de l’apport de la totalité du capital de la société Laboratoires Doliage
Nicox also announced the completion of the acquisition of the Carragelose® anti-viral eye drop program from Marinomed Biotechnologie GmbH. This acquisition provides Nicox with an innovative anti-viral ophthalmic product which could be launched in Europe within two years, pending CE marking, for the management of viral conjunctivitis. As per the terms of the agreement, Nicox has acquired the rights to the Carragelose® anti-viral eye drop program through the acquisition of AVEye Biotechnologie GmbH, a wholly-owned affiliate of Marinomed which owns the entirety of the eye drop program.
For more information, please refer to:
- Press release dated September 16, 2014: Nicox acquires Carragelose® anti-viral eye drop program
- Press release dated September 25, 2014 (in French): Emission par Nicox de 1 240 636 actions en rémunération de l’apport de la totalité du capital de la société AVEye Biotechnologie GmbH